权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomarker Core

生物标志物核心

基本信息

批准号：
10409747
负责人：
TONY WYSS-CORAY
金额：
$ 40.06万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10409747
关键词：
Algorithmic Analysis Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer’s disease biomarker Amyloid beta-42 Amyloid beta-Protein Bioinformatics Biological Assay Biological Markers Biology Blood Blood Cells Cardiovascular Diseases Cells Clinical Clinical Management Collection Cytometry DNA Data Data Analyses Data Set Databases Dementia Detection Development Diabetes Mellitus Disease Equipment and supply inventories Feces Fibroblasts Gene Expression Genetic Glial Fibrillary Acidic Protein Goals Human Image Immune Individual Information Dissemination Lead Light Liquid substance Measurement Measures Methods Mission Molecular Nerve Degeneration Neurodegenerative Disorders Parkinson Disease Parkinson&apos s Dementia Participant Pathologic Processes Peripheral Blood Mononuclear Cell Phenotype Plasma Populations at Risk Process Proteome Proteomics Publishing Quality Control RNA Reproducibility Research Research Personnel Sampling Sensitivity and Specificity Signal Transduction Skin Source Standardization T-Cell Receptor Technology Time Tissues Training Support Work analysis pipeline base bioinformatics tool biomarker performance data management data sharing experience genetic variant gut microbiome imaging modality member microbiome molecular marker multiple omics neurofilament neuropathology next generation novel novel marker novel therapeutics public database receptor expression research study skin microbiome stool sample tau Proteins tau-1 tissue biomarkers tool transcriptome transcriptome sequencing transcriptomics web portal whole genome

项目摘要

1. SUMMARY (Biomarker Core) Biomarkers have enormous value for the detection, management, and treatment of disease, but also for the development of novel therapeutics. The utility of biomarkers is most evident in the management of cardiovascular disease and diabetes, but biomarkers, especially predictive, easily obtainable ones, are still largely absent with respect to neurodegenerative diseases. The best fluid biomarkers currently available for Alzheimer’s disease (AD) include; Aβ, tau, and neurofilament in CSF, a biofluid which is difficult to collect in healthy, at-risk populations or on a repeated basis. Other biomarkers for AD include imaging modalities which are often very expensive or have low sensitivity and specificity at the individual level. The members of this core have considerable experience in unbiased multi-omic screens and data analysis and, over the years, have published numerous studies towards developing new biomarkers for neurodegenerative and other diseases. Enabled by the current ADRC, the core leaders and collaborators have used biospecimens from Stanford ADRC participants and generated extensive preliminary data with unbiased deep immune phenotyping, proteomics, and transcriptomics of human CSF resident cells, and discovered novel Parkinson's disease (PD) biomarkers. Based on this expertise, the mission of this Biomarker Core is to facilitate the discovery of novel biomarkers for AD and PD, as well as new biology underlying the pathological processes that lead to dementia in line with the core mission of the NAPA. This will be achieved by pursuing the collection of genetic and molecular measurements from a broad source of tissues from ADRC participants; the processing and dissemination of this information in useable formats through web portals and other means (i.e., “Deep Phenotyping Database”); the analysis and bioinformatics integration of the collected information with clinical and imaging data, as well as information from public databases; and the development and dissemination of new data analysis algorithms and pipelines.

1. 概述（生物标志物核心）